One-year results of the national breast and cervical cancer screening program: Giresun province in the black sea region

Breast and cervical cancer screening results

Authors

Keywords:

breast cancer screening, women’s health, human papilloma virus, cervical cancer screening

Abstract

Background/Aim: Increasing the survival rate of patients with breast and cervical cancers is possible by early diagnosis through screening individuals for cancer in the asymptomatic period. Especially during the COVID-19 pandemic period, the possibility of early diagnosis in breast and cervical cancers has decreased due to the decrease in cancer screening applications. The aim of cancer screening is to increase the survival of patients by detecting precancerous lesions early. The purpose of our study is to evaluate the application and results of breast and cervical cancer screening in the Black Sea region’s Giresun province.

Methods: This is a cross-sectional and descriptive study. The results of patients who were admitted to the Giresun Early Diagnosis Cancer Screening and Education Center between July 1, 2021, and June 28, 2022, were examined. The mammography report results of women aged 40–69 years who applied to the cancer screening center for breast cancer screening, and the HPV and Pap smear results of the patients aged 30–65 years who applied for cervical cancer screening, were evaluated retrospectively through the public health management system. Mammography results were evaluated with BIRADS (Breast Imaging Reporting and Dated System) scoring. The type of HPV and the cytology results from cervical swab samples were analyzed for cervical cancer screening.

Results: A total of 3567 people underwent mammography. Per the mammography results, the percentage of those with BIRADS 0 was 7.7% (n=278), the percentage of those with BIRADS 1–2 was 91% (n=3256), the percentage of those with BIRADS 4 was 0.7% (n=25), and the percentage of those with BIRADS 5 was 0.14% (n=5). HPV-DNA and cervical cytology examinations were performed for cervical cancer screening in 2326 patients. As a result of cervical cancer screening, HPV positivity was found in 6.44% (n=150) patients, and 14 different HPV types were found in the positive samples. When HPV types were examined, the two most common types were HPV type 16 (13.6%) and type 56 (11.9%). When the HPV types were examined in the positive samples, the two most common types were HPV type 16 (13.6%) and type 56 (11.9%). HPV type 18 was the least detected HPV type in patients (3.7%). When the Pap smear screening results of the 150 cases with positive screening results were examined, 3.33% were ASC-US (atypical squamous cells of undetermined significance), 22% were reported as infection, and 62.6% were normal.

Conclusion: The role of primary care physicians directing patients registered in their coverage area to cancer screening programs is especially effective in raising society’s awareness and education on the issue. As a result, it is important that primary care physicians and related specialist physicians, together with cancer early detection and screening centers, adopt a supportive stance towards these programs in order for them to be implemented effectively.

Downloads

Download data is not yet available.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, and Jemal A, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. DOI: https://doi.org/10.3322/caac.21492

TUIK. Death and Cause of Death Statistics, 2019. 2019 [cited 2021 July 17]; Available from: https://data.tuik.gov.tr/Bulten/Index?p=Olum-ve Olum-Nedeni-Istatistikleri-2019-33710.

Şahin S, Early diagnosis and screening programs in cancer. ETD. 2015;54 41-5.

Society AC, Cancer Facts & Figures 2012. 2012, Atlanta: American Cancer Society.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. DOI: https://doi.org/10.1002/ijc.29210

Kan Ö, Görkem Ü, Bariş A, Koçak Ö, Toğrul C, and Yildirim E, Evaluation of the frequency of human papillomavirus (HPV) in women admitted to cancer early diagnosis and screening training centers (CEDSEC) and analysis of HPV genotypes. Turk Hij ve Deney Biyol Derg. 2019;76(2):163-8. DOI: https://doi.org/10.5505/TurkHijyen.2018.47123

Turkey Cancer Statistics. 2015, Department of Cancer.

Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2):278-85. DOI: https://doi.org/10.1002/ijc.20244

Kose FM and Naki MM, Cervical premalignant lesions and their management. J Turk Ger Gynecol Assoc. 2014;15(2):109-21. DOI: https://doi.org/10.5152/jtgga.2014.29795

WHO. Screening and early detection. 2021 [cited 2021 July 17]; Available from: https://www.euro.who.int/en/healthtopics/noncommunicablediseases/cancer/policy/screening-and-earlydetection.

Health TRMo, Turkey cancer control plan 2013-2018. Part 3. Cancer screenings. 2016: Ankara. p. 40.

Keskinkılıç B, Gültekin M, Karaca AS, Öztürk C, Boztaş G, and Karaca M, Turkey Cancer Control Program. Ankara: T.R. Ministry of Health. Public Health Institution of Turkey. 2016.

Akova İ, Hasdemir Ö, and Türkoğu H, Evaluation of Breast Cancer Screening in Women aged 40-69 in a Province. Bozok Medical Journal. 2019;9(1):89-92.

Kayhan A, Gürdal SÖ, Özaydın N, Öztürk E, Cabıoğlu N, Arıbal E, et al. First Round Results of A Long Term Population- Based Breast Cancer Screening Program From Bahcesehir. The Journal of Breast Health. 2012;8(4):180-4.

Tunçez İH, Aksoy N, and Koç M, Ulusal Kanser Tarama Programı Sonuçları; Bir İl Örneği. Phnx Med J. 2021;3(2):69-73. DOI: https://doi.org/10.38175/phnx.922780

Ergünay K, Mısırlıoğlu M, Fırat P, Tuncer ZS, Tuncer S, and Ustaçelebi Ş, Investigation of Human Papilloma Virus DNA and Typing of the Virus in Cytologically Anomaly Detected Cervix Samples. Bulletin of Microbiology. 2007;41:219-26.

Deshou H, Changhua W, Qinyan L, Wei L, and Wen F, Clinical utility of Liqui-PREP cytology system for primary cervical cancer screening in a large urban hospital setting in China. J Cytol. 2009;26(1):20-5. DOI: https://doi.org/10.4103/0970-9371.54863

Korkmaz F and Gencer M, Outpatient Screening Pap Smear Results. Anatol J Clin Investig. 2014;8(1):17-20.

Zorzi M, Del Mistro A, Farruggio A, de'Bartolomeis L, Frayle-Salamanca H, Baboci L, et al. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. BJOG. 2013;120(10):1260-7; discussion 1267-8. DOI: https://doi.org/10.1111/1471-0528.12272

Levi JE, Martins TR, Longatto-Filho A, Cohen DD, Cury L, Fuza LM, et al. High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, Sao Paulo, Brazil. Cancer Prev Res (Phila). 2019;12(8):539-46. DOI: https://doi.org/10.1158/1940-6207.CAPR-19-0076

Zhang J, Cheng K, and Wang Z, Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China: a meta-analysis. Arch Gynecol Obstet. 2020;302(6):1329-37. DOI: https://doi.org/10.1007/s00404-020-05787-w

Monsonego J, Cox JT, Behrens C, Sandri M, Franco EL, Yap PS, et al. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. Gynecol Oncol. 2015;137(1):47-54. DOI: https://doi.org/10.1016/j.ygyno.2015.01.551

Derbie A, Mekonnen D, Nibret E, Maier M, Woldeamanuel Y, and Abebe T, Human papillomavirus genotype distribution in Ethiopia: an updated systematic review. Virol J. 2022;19(1):13. DOI: https://doi.org/10.1186/s12985-022-01741-1

Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomataram I, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol. 2019;20(3):394-407. DOI: https://doi.org/10.1016/S1470-2045(18)30836-2

Downloads

Published

2023-01-14

Issue

Section

Research Article

How to Cite

1.
Gürel Köksal N, Köksal M. One-year results of the national breast and cervical cancer screening program: Giresun province in the black sea region: Breast and cervical cancer screening results. J Surg Med [Internet]. 2023 Jan. 14 [cited 2024 Jul. 23];7(1):44-7. Available from: https://jsurgmed.com/article/view/7483